Amoebicidal effect of 5,5′-[(4-nitrophenyl)methylene]bis-6-hydroxy-2-mercapto-3-methyl-4(3H)-pyrimidinone), a new drug againstEntamoeba histolytica

Entamoeba histolyticais a cosmopolitan protozoan parasite that can produce infections in the intestine and some organs (liver, lungs, and brain), with worldwide prevalence. There are treatments againstE. histolytica(antiparasitics), but as the drugs used in these treatments have presented some type of resistance and/or side effects, there are cases with complications of this disease. Therefore, it is necessary to develop new drugs aimed at a specific therapeutic target against this parasite. Here, we used the compound 5,5 '-[(4-nitrophenyl)methylene]bis(6-hydroxy-2-mercapto-3-methyl-4(3H)-pyrimidinone) in the patenting process (called D4). D4 has a reported specific use against a glycolytic enzyme, the triosephosphate isomerase ofTrichomonas vaginalis(TvTIM). We determined that D4 has an amoebicidal effect in in vitro cultures, with an IC(50)value of 18.5 mu M, and we proposed a specific site of interaction (Lys77, His110, Gln115, and Glu118) in the triosephosphate isomerase ofE. histolytica(EhTIM). Furthermore, compound D4 has favorable experimental and theoretical toxicity results. Therefore, D4 should be further investigated as a potential drug againstE. histolytica.

Automated summary

Entamoeba histolyticais a globally prevalent protozoan parasite with resistance and side effects to current treatments, motivating the search for new therapeutic targets. Compound D4 has shown amoebicidal effects againstE. histolytica, making it a potential candidate for further drug development. Further research is needed to explore the efficacy of D4 as a drug against E. histolytica.